LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

11.73 0.6

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.34

Max

11.73

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+170.32% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-331M 1B
Vorige openingsprijs	11.13
Vorige sluitingsprijs	11.73

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 jun 2026, 23:22 UTC

Winsten

Belangrijke Marktbewegers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 jun 2026, 23:09 UTC

Populaire aandelen

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 jun 2026, 20:51 UTC

Winsten

Costco Reports 15% Sales Growth in May

3 jun 2026, 20:43 UTC

Winsten

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 jun 2026, 23:48 UTC

Marktinformatie

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 jun 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 jun 2026, 23:35 UTC

Marktinformatie

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 jun 2026, 23:15 UTC

Marktinformatie

Winsten

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 jun 2026, 22:08 UTC

Populaire aandelen

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 jun 2026, 21:54 UTC

Marktinformatie

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 jun 2026, 21:18 UTC

Winsten

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 jun 2026, 21:15 UTC

Winsten

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 jun 2026, 21:13 UTC

Winsten

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 jun 2026, 21:13 UTC

Winsten

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 jun 2026, 21:12 UTC

Winsten

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 jun 2026, 21:09 UTC

Winsten

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 jun 2026, 21:03 UTC

Winsten

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 jun 2026, 20:43 UTC

Winsten

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 jun 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 jun 2026, 20:37 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 jun 2026, 20:35 UTC

Winsten

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 jun 2026, 20:17 UTC

Winsten

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 jun 2026, 20:17 UTC

Winsten

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q Adj EPS $2.44 >AVGO

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q EPS $1.91 >AVGO

3 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q Rev $22.19B >AVGO

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

170.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 170.32%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.